Introduction
Most sensorineural hearing loss cases are caused by hair cell loss, which results in secondary degeneration of spiral ganglion neurons (SGNs) that normally innervate the organ of Corti before hair cell degeneration in many animal models (Ylikoski et al., 1993) . Because cochlear implants rely on SGNs for transmitting signals to the central auditory centers, loss of the neurons reduces the benefit of implanted devices and could result in poor performance if the SGN survival is substantially below a functioning threshold (Clopton et al., 1980; Incesulu and Nadol, 1998) . Neurotrophins (NTs) [e.g., brain-derived neurotrophic factor (BDNF) and NT-3] play essential roles in cochlear development (Farinas et al., 1994; Ernfors et al., 1995) . NT-3 shows significant long-term cochlear expression, whereas the receptors for both NTs are expressed into the adult stage (Fritzsch et al., 1999; Kawamoto et al., 2001; Rubel and Fritzsch, 2002) . Exogenous applications of BDNF directly into the cochlea rescue SGNs from degeneration in animal models in which degeneration of SGNs is caused by hair cell loss in adult animals after ototoxic insults Miller et al., 1997) . However, the short plasma half-life and poor pharmacokinetics of BDNF greatly reduces its efficacy in vivo. Direct uses of BDNF have generated poor results in clinical trials (Saragovi and Gehring, 2000; Gillespie and Shepherd, 2005) .
Recently, a number of small-molecule tyrosine receptor kinase B (TrkB) receptor agonists have been developed Liu et al., 2010) . These compounds readily crossed the blood-brain barrier and activate TrkB receptors in neurons with a half-effective concentration (EC 50 ) below 50 nM (Jang et al., 2010). 7,8-Dihydroxyflavone (7,8-DHF) was tested in a number of neurodegenerative animal models and show promising results (Blugeot et al., 2011; Devi and Ohno, 2012) . However, the effect of 7,8-DHF has not been examined for auditory neuroprotection. In addition, more potent 7,8-DHF analog with better in vivo pharmacokinetics has also been developed. Based on extensive structural-activity relationship studies, a new compound, 7, 8, 8, , was identified. The new compound at least doubled the potency of 7,8-DHF in stimulating TrkB phosphorylation and demonstrated some promising effect in protecting the SGNs (Yu et al., 2012) . In this study, we conducted a thorough investigation for the neuroprotective effects of 7,8,3Ј-THF and 7,8-DHF, using both organotypic cultures of mouse cochlea and an in vivo model of degeneration of the peripheral auditory SGNs. Our in vivo studies used the conditional connexin26 (cCx26) knock-out mice . The secondary degeneration of SGNs in this line of genetically modified mice has been characterized in studies of the most common form of prelingual non-syndromic deafness in humans (Sun et al., 2009; . We found that these small-molecule compounds phosphorylated the TrkB receptors as well as key molecules of downstream TrkB signaling and protected SGNs in a TrkB-dependent manner. The survival of SGNs was enhanced by both compounds with high potency in vitro and in vivo. The excitability of the SGNs rescued by these small-molecule TrkB agonists was also confirmed by both patch-clamp and eABR recordings. These results raise the hope of overcoming a major hurdle of drug delivery for the translational uses of the BDNF in auditory neuroprotection to benefit patients.
Materials and Methods
In vitro assays performed with the organotypic cochlear cultures. Animal use protocols in this study were approved by the Emory Institutional Animal Care and Use Committee. C57BL/6 (Charles River) and TrkB F616A mice (either sex) were used to obtain cochlear tissues used in the cultures. We only used the segment isolated from the middle cochlear turn to ensure consistency. Cochleae from postnatal day 1 (P1) or P2 were dissected in ice-cold HBSS (Invitrogen). Detailed tissue dissection procedures were given in our published papers (Chang et al., 2008) . The cochlear explants were cultured on glass coverslips prepared by coating with 500 g/ml poly-D-lysine (Invitrogen) and 50 g/ml laminin (Invitrogen) dissolved in HBSS for 2 h at 37°C. A defined serum-free culture medium, which contained DMEM (SigmaAldrich), 10 l/ml N2 supplement (Invitrogen), 25 mM HEPES (SigmaAldrich), 6 mg/ml glucose, and 1 mM gentamicin (Sigma-Aldrich), were used. The cultures were maintained at 37°C in a 6.5% CO 2 incubator, and culture medium was replaced every 24 h. Samples cultured for 72 h were used in the immunoassays. In different culture experiments, 100 ng/ml BDNF (Invitrogen), 300 nM 7,8,3Ј-THF or 7,8-DHF (purity Ͼ99%; Indofine Chemical Company) was added as indicated in text.
The detailed immunolabeling protocol was given previously in our published papers (Sun et al., 2005) . Briefly, samples were first incubated in primary antibody (1:400) at 4°C overnight. A mouse monoclonal antibody against class III ␤-tubulin (TUJ1; catalog #MMS-435P; Covance) was used to label SGNs in cultures. Processed samples were mounted in an antifade solution (Fluoromount-G; Southern Biotechnology Associates), which also contained DAPI to label cell nuclei. Fluorescent images were acquired by a confocal microscope (Zeiss LSM; Carl Zeiss) and analyzed using NIH Image J software package (http://rsbweb.nih.gov/ij/features.html).
In Western blotting, we used a total of 24 cultured cochleae. These cultures were divided into four groups (n ϭ 6 in each group) by their treatment (30 min) with BDNF (100 mg/ml), 7,8-DHF (300 nM), 7,8,3Ј-THF (300 nM), or defined medium only with no supplement. The cochlear tissues in the four groups were rapidly collected into an Eppendorf tube and snap frozen in dry ice. Details of the Western blot protocol can be found in our previously published work (Ahmad et al., 2007) . The bands of TrkB, phosphorylated TrkB (p-TrkB), Erk, and p-Erk were detected on the same membrane using antibodies against TrkB (catalog #4603S, 1:1000; Cell Signaling Technology), p-TrkB (catalog #sc135645, 1:200; Santa Cruz Biotechnology), Erk1/2 (catalog #9102, 1:1000; Cell Signaling Technologies), and p-Erk1/2 (catalog #9106S, 1:1000; Cell Signaling Technologies). Secondary antibodies were goat anti-rabbit (1: 3000) or anti-mouse (1:3000) IgG conjugated to the HRP (Bio-Rad).
In vivo delivery of the small-molecule TrkB agonist and morphological evaluations of the effect. cCx26 null mice younger than P2 (either sex) were cryo-anesthetized by placing the pups on ice for 3 min. We used a retro-auricular approach to expose the tympanic membrane and tympanic ring. The stapedial artery and round window niche was exposed, and a small absorbable gelatin sponge (2-3 mm 3 ; Gelfoam; catalog #59-9863; Pfizer) soaked with 15 l of 7,8,3Ј-THF (200 M, dissolved in PBS containing 0.1% DMSO) was placed on the round window membrane. We always performed the surgical procedures for the left ear. The contralateral (right side) cochleae were not treated and used as controls. The same procedure was repeated at P30 to give the second application of 7,8,3Ј-THF. At P60, the animals were killed after auditory brainstem response (ABR) thresholds were tested. Details of ABR test methods are given in our previously published work (Ahmad et al., 2007) . Both cochleae were processed and compared in histological analysis to evaluate effects of BDNF small molecules in promoting the survival of SGNs in vivo. Consecutive midmodiolar cochlear resin sections (5 m in thickness) were cut with a microtome (model HM 335E; Microm). Tissues were fixed by transcardiac perfusion of 4% paraformaldehyde (PFA) dissolved in the PBS. Cochleae were dissected out and subsequently perfused via the oval window with 2% PFA and 2.5% glutaraldehyde in PBS and postfixed at 4°C overnight. Decalcification was performed for 72 h at 4°C in 0.35 M EDTA in PBS, pH 7.4. The cochlear samples were then immersed in 2% osmium tetroxide for 2 h, followed by gradual dehydration in alcohol of increasing grades, infiltrated, and embedded in epoxy resin. Cochlear sections were stained with toluidine blue and examined with a light microscope.
Electrophysiological recordings. Borosilicate glass capillary pipettes (Sutter Instruments) were pulled on a micropipette puller (P-2000; Sutter Instruments), and the electrodes (with a resistance of 1-3 M⍀) were fire polished (MF-830; Narishige) before uses. HEPES-buffered HBSS solution was used as the external bathing solution, which contained the following (in mM): 137 NaCl, 0.2 Na 2 HPO 4 , 5.4 KCl, 0.4 KH 2 PO 4 , 1 MgCl 2 , 1.2 CaCl 2 , and 10 HEPES. The pipette internal solution contained the following (in mM): 140 KCl, 2 MgCl 2 ⅐2H 2 O, 1.2 CaCl 2 , 10 EGTA, and 10 HEPES, pH buffered to 7.3 with KOH. Coverslips with cultured SGNs were placed in a perfusion chamber mounted on a Carl Zeiss upright fixed-stage microscope (AxioSkop II). The series capacitance was compensated, and a tight seal (Ͼ1 G⍀) was maintained during recordings. Experiments were controlled by Clampex software (version9.1). Signals from a patch-clamp amplifier were digitized via a Digidata 1322A interface (Axon Axopatch 200B; Molecular Devices). Data were analyzed offline using pClamp (version 9.2; Molecular Devices) and Origin 7.0 (OriginLab) software.
Electrically evoked ABRs (eABRs) were recorded by delivering biphasic rectangular pulses generated from an isolated pulse stimulator (model 2100; A-M Systems) through an electrode placed on the round window membrane. The return electrode was placed in the neck muscle as the reference. These current pulses had alternating polarity to provide charge balancing. The pulses had a width of 80 s and an interpulse interval of 10 ms. The amplitude was manually controlled between 50 and 800 A. Three recording electrodes were placed subcutaneously at the nose, the right and left mastoid areas to record the eABRs. These signals were amplified and filtered first through a differential amplifier (DAM 70; WPI) and then by a direct current amplifier (LPF 202A; Warner Instruments). The signals were digitized by a Digidata 1322A (Molecular Devices) and recorded using the Clampex 9.2 (Molecular Devices) software package. The first positive peak (P1) in the eABR waveforms was always blocked by the electrical artifact. We therefore used the first negative peak and the second positive peak (wave N1-P2) to measure the threshold of the eABRs, which were defined as the amplitude of stimulus current that evoked a consistently visible N1-P2 waveform (see Fig. 5 ). N1-P2 amplitudes for all current levels in the experimental and control animals were analyzed using repeated-measures ANOVA, and t tests were used to analyze measurements at suprathreshold current levels.
Quantitative histological data analyses. The cultured spiral ganglia were imaged using a confocal microscope using a 40ϫ oil-immersion lens (numerical aperture 1.2; Zeiss LSM; Carl Zeiss). The distance between each optical section was 10 m. SGNs were specifically immunolabeled with an antibody against ␤-tubulin, which labeled both cell body and neuritis (see Figs. 1-4). NIH Image J software (version 1.63) was used for quantitative analysis. Cells were counted in each optical section when the nucleus comprised Ͼ40% of the soma area. Because SGNs are ϳ10 m in diameter and optical sections were taken every 10 m, this counting procedure greatly reduced the chances of each SGN being double counted. Neuronal counts from each optical section were summed for all the sections to give the total count of neurons in each explant of cochlea culture. Neuronal density per each 100 m 3 was subsequently calculated. SGN density in vivo was quantified from midmodiolar sections of mouse cochleae obtained from P60 old mice. The resin sections were cut in 5 m thickness. Two sections separated by 40 m were used in counting the survived SGNs to minimize the possibility of double counting because the largest soma diameter should be Ͻ20 m. A straightforward point-counting method (Leake and Hradek, 1988) was used to estimate SGN density. The number of SGNs in the section was divided by the area of the Rosenthal's canal to obtain the density of SGNs. Counting errors were corrected by using the Abercrombie's equation (Guillery, 2002) : T/T ϩ h, in which T is the section thickness, and h is the mean diameter of the SGNs. The Student's t test was used to determine the significance of differences between various groups, and a p value of Ͻ0.05 was used. Both perikaryal area and cell circularity were measured directly in the NIH Image J program after outlining the innermost boundary of the myelin sheath enveloping the perikaryon. Circularity is calculated as: 4A/L2, where A is area, and L is the perimeter. All quantitative analyses were performed in a blind manner by two independent investigators to ensure the consistency of counting. GraphPad Prism 5 (GraphPad Software) and Origin 7.0 (OriginLab) software were used in data analysis. Statistical analyses were performed using either one-way ANOVA with post hoc Tukey's tests or Student's two-tailed unpaired t tests. Data were presented as mean Ϯ SEM. The level of significance was set at p Ͻ 0.05.
Results

7,8,3-THF and 7,8-DHF greatly promoted the survival of SGNs in organotypic cochlear cultures
The neuroprotective effects of 7,8,3Ј-THF and 7,8-DHF were first evaluated in vitro in the culture media used in organotypic cultures. Hair cells were killed by applying gentamicin (Zheng and Gao, 1996) to eliminate the supply of endogenous NTs. Cultured in a defined media for 3 d, we found that SGN soma density (Fig. 1A,D ,G,J), neurite density (Fig. 1G ,E,H,K), and length (Fig.  1C ,F,I,L) were significantly increased in the presence of either 7,8,3Ј-THF (300 nM) or 7,8-DHF (300 nM) when compared with a control condition when TrkB receptor was not activated. The detailed comparison data are given in the Table 1 and Figure 2j -l, which suggested that the two smallmolecule TrkB agonists exhibited a potency in promoting the in vitro survival of SGNs similar to that of BDNF. In the absence of any TrkB agonists, SGN soma density was ϳ17 neurons/100 m 3 after 3 d in culture (Fig. 1G,J) . Addition of 7,8,3-THF (300 nM) or 7,8-DHF (300 nM) increased the SGN density to Ͼ100 neurons/100 m 3 (Fig. 1J , p Ͻ 0.001), which was similar to that obtained when 100 ng/ml BDNF was added in the culture media (Table 1 ). The neurite densities (Fig. 1K ) of the cochlear explants as well as the neurite lengths (Fig. 1L ) obtained in the presence of either 7,8,3Ј-THF or 7,8-DHF were also increased to levels similar to those obtained when BDNF was supplemented in the cultured media ( Fig. 1 ; Table 1 ) and were significantly greater than those obtained when SGNs were cultured in defined medium only (p Ͻ 0.01; Table 1 ). To test the dose responses, we found that increasing the concentrations of 7,8,3Ј-THF gradually increased the number of survived SGNs (Fig. 2) . Saturated concentration was found at ϳ300 nM, and the EC 50 was estimated to be 44 nM (Fig. 2g) . By a similar procedure, we estimated that the EC 50 of 7,8-DHF to be 86 nM. These results demonstrated high potency of 7,8,3Ј-THF and 7,8-DHF in promoting survival of SGN soma and neurites and were consistent with previously reported survival promotional effects by BDNF obtained in organotypic cochlear cultures (Barclay et al., 2011) .
NT-3 provides additive support to BDNF in promoting survival of cultured murine SGNs (Hegarty et al., 1997) . When the saturating concentrations of BDNF (100 ng/ml) or NT-3 (100 ng/ml) (Malgrange et al., 1996) were applied together with 7,8,3Ј-THF (200 nM) in the organotypic cochlear cultures, only the combination of 7,8,3Ј-THF and NT-3 provided the additive protective effects as measured by SGN density, neurite density, and neurite length (Fig. 3) . These results are consistent with the idea that the BDNF small molecules we tested in this study specifically activated the TrkB receptors. rosine residues on its intracellular domain, leading to the activation of specific downstream intracellular signaling pathways (Middlemas et al., 1994) . Immunofluorescent staining of cochlear sections with an antibody specific to phosphorylated TrkB showed that applications of 7,8,3Ј-THF to the otic bulla yielded a positive immunoreactivity at the applied side of the cochlea, whereas the contralateral untreated cochleae in the same animal was negative (comparing Fig. 4A-D) . Immunoblotting analysis demonstrated that treatments with 7,8,3Ј-THF, 7,8-DHF, and BDNF (a positive control) significantly increased the phosphorylation of both TrkB and Erk1/2 (Fig. 4E) . In contrast, the total amount of TrkB and Erk1/2 protein remained unchanged (Fig. 4E) . These results indicated that 7,8,3Ј-THF and 7,8-DHF activated TrkB receptors as well as the downstream MAPK pathway. A point mutation F616A in the TrkB renders it sensitive to the blockage by 1-naphthyl-methyl protein phosphatase 1 (1NMPP1) (Bishop et al., 2000) , which was used to null functions of the TrkB in a controlled manner . To further test whether the neuroprotective effect of 7,8,3Ј-THF is dependent on the TrkB activation, we used cochleae isolated from TrkB F616A knock-in mice. Contrary to the dramatic increase of SGN density by the applications of 7,8,3Ј-THF in cochlear cultures of wild-type (WT) mice (Fig. 1) , the protective effects of 7,8,3Ј-THF were abolished by blockage of TrkB with 100 nM 1NMPP1 (Fig. 4F-I ) . As a control test, we found that the survival-promoting effect exerted by the NT-3 through the TrkC receptor was preserved in the presence of 1NMPP1 (Fig. 4 H, I ) in cochlear cultures dissected from the TrkB F616A mice. These results further support the idea that 7,8,3Ј-THF selectively activates TrkB in exerting its neuroprotective actions on SGNs.
Survived SGNs show electrical excitability in vitro and in vivo
The electrical excitability of SGNs was tested in vitro by patch-clamp recordings and in vivo by recording eABRs to assess the neuronal functions after rescue. Transient inward sodium currents were reliably elicited by depolarizing voltages more positive than Ϫ40 mV from a holding potential of Ϫ80 mV in freshly isolated SGNs (Fig. 1A) and from neurons cultured with 7,8,3Ј-THF for 3 d (Fig. 5C) . However, the average amplitude of the peak sodium currents (measured at ϩ20 mV) was substantially larger than that obtained from freshly dissected SGNs [1003 Ϯ 89 pA (n ϭ 10) compared to 661 Ϯ 60 pA (n ϭ 10); p Ͻ 0.01] (Fig. 5E ). Under the current clamp, a single action potential (AP) was evoked by suprathreshold current stimuli from both freshly dissected and 7,8,3Ј-THF-treated SGNs (Fig. 5 B, D, respectively) . The threshold currents needed to elicit APs were similar under both conditions [90 Ϯ 12 pA (n ϭ 10) vs 93 Ϯ 14 pA (n ϭ 10)] (Fig. 5F ). These data obtained in vitro indicated that SGNs survived in cultures were able to generate robust inward sodium currents to trigger the APs. We also recorded eABR responses to monitor the function of survived SGNs in vivo. Examples of eABR traces recorded from the cochlea of WT animals, cCx26 null mice treated with 7,8-DHF, and their controls (untreated) are described in Figure  5 , G and H. The threshold stimulus currents needed to evoke the N1-P2 waves were compared among the three groups using a one-way ANOVA with post hoc Tukey's test. Thresholds were significantly lower in 7,8-DHF-treated cCx26 null mice (412 Ϯ 55 A, n ϭ 5) than those observed in untreated cCx26 null mice (634 Ϯ 85 A, n ϭ 5) (Fig. 5H ) . As expected, sound-evoked ABR tests showed that the acoustic hearing in animals was not restored as a result of the loss of hair cells (see Fig. 7a ).
Morphological evidence supporting that 7,8,3-THF and 7,8-DHF protected SGNs from degeneration in cCx26 null mice
Our previous studies demonstrated that hair cells die rapidly in the middle and basal turns of cCx26 null mice during P14 -P21. Most SGNs in the Rosenthal's canal were degenerated by P60, except those in the apical turn (Sun et al., 2009; . Therefore, we used cCx26 null mice to test the in vivo efficacy of 7,8,3Ј-THF and 7,8-DHF in protecting the SGNs. We applied the compounds only to the left bulla. The contralateral ear was used as an untreated control to compare the protective effects in the same animal. Both cochleae were examined 2 months after birth.
Cochlear sections were examined for the morphological rescue effects. As expected, sections obtained from WT animals demonstrated densely packed SGNs and nerve fibers of all cochlear turns of the Rothenthal's canal (Fig. 6I-L) . These results were in sharp contrast to results obtained from untreated cCx26 null mice, in which a substantial loss of SGNs was observed (Fig.  6A-D) , especially in the middle and basal turns (Fig. 6 A, B , respectively). In the contralateral cochlea of the same animal in which 7,8,3Ј-THF or 7,8-DHF was used, we observed that the SGNs were significantly preserved (Fig. 6, compare rows A-D,  E-H ) . SGN density was calculated at four different cochlear locations: basal (B), middle (M), middle-apical (A2), and topapical (A1), summarized in Figure 6M and Table 1 . Mean values of the SGN soma area and cell circularity at the location basal and middle locations were also examined. Soma size and cell circularity of SGNs at basal and middle turns in untreated cCx26 null cochleae were significantly reduced ( p Ͻ 0.01; Table 1 ). In comparison, 7,8,3Ј-THF treatment increased the soma size and cell circularity to approximately the same level as that of normal cochleae (Fig. 7b,c, dashed lines) .
Discussion
NTs regulate the development and maintain the survival of neurons in the PNS and CNS (Lewin and Barde, 1996) . In the auditory system, most cases of sensorineural hearing loss are caused by loss of hair cells in the cochlea (Dallos et al., 1996; Hudspeth, 1997) . The hair cells and surrounding supporting cells are also the primary sources of neurotrophic support for the SGNs (Ylikoski et al., 1993; Schecterson and Bothwell, 1994; Rubel and Fritzsch, 2002) . Death of hair cells usually triggers secondary degeneration of SGNs, starting with the loss of synaptic terminals followed by the disintegration of cell bodies, although the severity and time course of this process may vary among different species and animal models (Pan et al., 2011; Shibata et al., 2011) . Depending on the species, the degeneration time course ranges from a few weeks to years (Otte et al., 1978; Leake and Hradek, 1988; Jyung et al., 1989) , which results in Ͼ80% loss of SGNs in a few weeks in many animal models deafened by ototoxic drugs to selectively kill hair cells (Leake and Hradek, 1988; Hardie and Shepherd, 1999; Dodson and Mohuiddin, 2000) . It is also realized that degeneration of SGNs in humans is not correlated with the loss of hair cells and the time courses of degeneration are variable among different species (Leake and Hradek, 1988; Dodson and Mohuiddin, 2000; Linthicum and Fayad, 2009) the regeneration of hair cells. Exogenous application of NTs rescues SGNs from degeneration resulting from the loss of cochlear hair cells (Ernfors et al., 1996; Staecker et al., , 1998 Shinohara et al., 2002; Gillespie and Shepherd, 2005; Rejali et al., 2007) . These encouraging results have stimulated enormous interest in translational research aimed at applying exogenous NTs to promote the survival of residual SGNs in the cochlea of patients with severe sensorineural hearing loss (Shinohara et al., 2002; Gillespie and Shepherd, 2005; Pettingill et al., 2007; Shepherd et al., 2008) . However, none of these studies have advanced to clinical trials, now 16 years after the first series of papers were published (Ernfors et al., 1996; Miller et al., 1997) . Because neuroprotective effects depend on the continuous presence of the BDNF (Gillespie et al., 2003) , how to prevent proteolytic breakdown of NTs to achieve long-term, recurring, and safe deliveries at desired dosages has been one of the major hurdles hindering the clinical translation (Pettingill et al., 2007) . The outcomes of several clinical trials using recombinant BDNF are disappointing (Ochs et al., 2000) . Presumably, this is attributable to poor delivery and the short in vivo half-life of BDNF (Thoenen and Sendtner, 2002) .
In this study, we provide several pieces of evidence demonstrating that 7,8-DHF and its derivative 7,8,3Ј-THF strongly activate TrkB receptors in SGNs in drug-treated ears. Both compounds promoted SGN survival and neurite growth in organotypic cultures in a dosedependent manner (Fig. 2) . Notably, 7,8,3Ј-THF displayed a low EC 50 of ϳ44 nM. In our published studies , we have clearly defined that 7,8-DHF does not activate TrkC. In addition, we also showed that blocking TrkB in TrkB F616A knock-in mice with 1NMPP1 antagonized the physiological actions of 7,8-DHF, supporting that TrkB receptor activation by 7,8-DHF accounts for its specific effect. In this study, the compound also demonstrated additive effects in promoting the SGN survival, as measured by both soma and neurite densities, as well as neurite growth in the presence of NT-3. In contrast, when combined with BDNF, no extra beneficial activity was observed (Fig. 3) . These data strongly support the idea that the small molecules tested here mimic the biological functions of BDNF and display additive activity as revealed by NT-3 and BDNF combination. Moreover, we showed that the survived SGNs were functional both in vitro and in vivo (Figs. 4, 5) , indicating that the compounds not only promoted the neuronal survival but also maintained physiological functions of SGNs. In addition to the prominent efficacy in promoting SGN survival in vitro, we also observed that both 7,8,3Ј-THF and 7,8-DHF significantly elevated the SGN numbers in the Rosenthal's canal of cCx26 null mice compared with untreated contralateral cochlea (Fig. 6) . Hence, these results support the idea that the novel small-molecule BDNF mimetics act as a potent TrkB agonist and provokes TrkB receptor activation in SGNs, as well as strongly enhance SGN survival in a mouse model of human congenital deafness. The differential rescue results we observed for the SGNs, namely more effective in the basal and middle turns and apparently less profound in the apex, are not reflections of the differential effects of the compounds we used but rather distinctive characters of the mouse model we used. The pattern of degeneration of SGNs in the cCx26KO mice is always more severe in the middle and basal turns but very minor in the apical turn (Sun et al., 2009; . Interestingly, some of the other genetically modified mice also show a similar pattern of degeneration of SGNs (Pan et al., 2011; Shibata et al., 2011) . Remarkably, the SGN survival-promoting effect was completely dependent on the TrkB receptors (Fig. 4) . This was demonstrated by the blockage of the TrkB F616A with 1NMPP1, which abolished the neurotrophic activities. In contrast, NT-3 remained active in promoting the SGN neuron survival (Fig. 4 H, I ), underscoring the fact that 7,8,3Ј-THF specifically exerted its neurotrophic action through TrkB receptors.
Our previous in vitro studies indicate that 7,8-DHF binds to the purified TrkB recombinant extracellular domain (ECD) in a 1:1 ratio, indicating that one molecule of TrkB receptor contains one 7,8-DHF ligand binding site . Recently, using a molecular modeling approach, we show that 7,8-DHF is inserted into a large cavity on the back of the leucine-rich repeat of the TrkB ECD . In this study, the Hill coefficient suggested that 7,8,3Ј-THF had a positive cooperativity in provoking spiral ganglion survival. Conceivably, these two small molecules share the same binding site on TrkB receptor. On the plasma membrane of the neurons, the active TrkB receptors exhibit as dimer on the ligand binding on each receptor. However, it remains unclear whether multiple receptor complexes occur on SGNs on 7,8,3Ј-THF stimulation. Dosage responses of our neuronal survival data suggest that additional in-depth investigation regarding the biophysical association between the small molecules and downstream activation of the TrkB receptor is needed. Presumably, other unknown binding targets also allosterically affect the ligand interaction with the TrkB receptor to yield the positive cooperativity we observed here.
Both 7,8-DHF and 7,8,3Ј-THF are flavonoid derivatives. They contain multiple hydroxy groups on the benzene rings. Because phenol or catechol groups are prone to be metabolized by glucuronidation, sulfation, and methylation in the liver or plasma, they usually possess relatively short half-lives in the circulation system, leading to poor oral bioavailability. However, for the purposes of this study, the compounds were applied locally to avoid the delivery problem in the systematic administration and to give us the ability to compare survival of SGNs between the two ears in the same animal. We used a small cube of an absorbable gelatin sponge soaked with 7,8,3Ј-THF on the round window membrane to deliver the drug. Conceivably, 7,8,3Ј-THF may be administrated topically by dropping the drug solution into the middle ear cavity of impaired ears. The cochlear implant is currently the only effective therapeutic treatment for patients suffering from severe sensorineural deafness. This device provides auditory cues by directly stimulating SGNs, thus bypassing the damaged or missing hair cells. The survival of SGNs in the cochlea is critical for the optimal performance of cochlear implants (Clopton et al., 1980; Incesulu and Nadol, 1998) . Previous studies revealed that 7,8-DHF has no detectable toxicities, even when given at high dosages in animal studies (Payá et al., 1993; Tasdemir et al., 2006) , suggesting that it has negligible systemic side effects. A number of recent studies using 7,8-DHF have shown promising therapeutic effects for numerous neurological diseases (Choi et al., 2010; Liu et al., 2010; Devi and Ohno, 2012) . Studies show that 7,8-DHF fully mimics BDNF and exhibits promising therapeutic effects in animal models of depression (Blugeot et al., 2011 ), Alzheimer's disease (Devi and Ohno, 2012) , and Rett syndrome . Compared with intracochlear infusion of BDNF, the local or systematic application of 7,8-DHF or 7,8,3Ј-THF should also be advantageous in terms of better pharmacokinetic properties than those observed with polypeptides. Conceivably, the identification of the promising small-molecule compounds (7, 8, has brought us one step closer to the effective translation of basic bench-top research of neuroprotection of SGNs into bedside clinical practice.
